European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.
about
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin CancerTopical PDT in the Treatment of Benign Skin Diseases: Principles and New ApplicationsCurrent evidence and applications of photodynamic therapy in dermatologyPhotodynamic Therapy and Non-Melanoma Skin CancerDrug delivery nanoparticles in skin cancersThe dermatoscopic universe of basal cell carcinomaLight-based therapies in acne treatmentPhotodynamic therapy in Bowen disease of the first web space of the hand.Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians.Pretreatment with ablative fractional laser changes kinetics and biodistribution of topical 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL).Primary care review of actinic keratosis and its therapeutic options: a global perspectiveTreatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia.Photodynamic Therapy Followed by Mohs Micrographic Surgery Compared to Mohs Micrographic Surgery Alone for the Treatment of Basal Cell Carcinoma: Results of a Pilot Single-Blinded Randomised Controlled Trial.Light-emitting diodes in photodynamic therapy in non-melanoma skin cancers--own observations and literature review.Skin reactions after photodynamic therapy are unaffected by 839 nm photobiomodulation therapy: A randomized, double-blind, placebo-controlled, clinical trial.Long-term recurrence of nonmelanoma skin cancer after topical methylaminolevulinate photodynamic therapy in a dermato-oncology department.A 10-Year Retrospective Analysis of Methyl Aminolevulinate Photodynamic Therapy Consultation at the Hospital de Braga.Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis.Is There a Relationship between the Stratum Corneum Thickness and That of the Viable Parts of Tumour Cells in Basal Cell Carcinoma?Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions.Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment.Dermoscopy in the diagnosis and management of basal cell carcinoma.Photodynamic therapy for basal cell carcinoma.Daylight photodynamic therapy with MAL cream for large-scale photodamaged skin based on the concept of 'actinic field damage': recommendations of an international expert group.Enhanced efficiency of cell death by lysosome-specific photodamage.Demethoxycurcumin in combination with ultraviolet radiation B induces apoptosis through the mitochondrial pathway and caspase activation in A431 and HaCaT cells.Daylight photodynamic therapy in Scotland.Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial.Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.Comparison of the Effect of Skin Preparation Pads on Transepidermal Water Loss in Ex Vivo Human SkinEuropean guidelines for topical PDT part 1 JEADV 2013; 27: 536-544.Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial.Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.Protoporphyrin IX formation after topical application of methyl aminolaevulinate and BF-200 aminolaevulinic acid declines with age.Non-invasive diagnosis of pink basal cell carcinoma: how much can we rely on dermoscopy and reflectance confocal microscopy?Is the thin layer of methyl aminolevulinate used during photodynamic therapy sufficient?Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis?
P2860
Q26777814-8697E871-2CD4-4C85-B8FC-F651E61DAD25Q26781377-64819A35-78E9-4A58-B5AD-B494FBBC40A7Q26822964-EABFE27F-9F13-4179-9969-C91D50D0145BQ28066173-9C49D512-162D-4F5C-AD75-8083B124FA60Q28390405-3FF347CA-12F7-4FEA-8978-EAD70C7400E9Q34041595-39B22E6E-B518-4159-9D9F-1F004255AF7BQ34477851-4483DFE9-7C0B-4008-BDC7-45DF71F8649DQ35069971-8B4A5B10-161D-4359-8E64-83C124211547Q35115492-E3755BCD-C7B5-4879-838C-D2D42E306AADQ35171163-33A45797-A9B1-4EBE-B782-F0B1AD150A95Q35217907-93D2FCCE-0275-486E-AA59-EF99BACA3D40Q35591195-73BFCF49-54FA-447A-9D3C-FD3E3B9AF43DQ35649171-377B6BAA-6B08-471B-B5FA-B5586CCEAD65Q35686724-FB40EDC4-61B1-4506-BA72-81AAD0721930Q35886599-93C4A4B5-0BDA-4998-84E6-F28E00BC2C22Q36382703-BF4290C4-03CE-458F-9260-6E2DEB748AC6Q36398295-C7A3BA2F-5ADA-4FE0-B47B-F0BE0B00E226Q36999991-0989B95C-0415-44F0-93A0-588C7108BEF6Q38265890-6743E7ED-4113-473C-A50E-DA01587EF45FQ38363378-62DDA3B1-ABB3-4060-892E-569A773FD46EQ38402878-EF639F7B-9225-4DD6-AB51-AB2ABB08B7EFQ38595324-FA2D42E2-5B86-4275-B564-ED043CAD386FQ38602861-934208F7-B739-4335-B136-36EE961EFBF2Q38628634-A9BAF52C-F2D5-429E-AFF8-94E322EEC7F3Q38629012-36723AF8-B9D3-42BB-8032-AC54C7F6B279Q38656448-FB818DCB-80A6-40BA-B3C8-ACAE47891A44Q38700212-6614F196-2BEE-4E61-9B0C-65EB4A406B94Q38782242-332C5414-C652-4ED3-814D-8FD9AA05BB88Q39198507-A2186AF1-A1CC-413E-8F5C-D0342663D7D3Q41494871-1058061C-7CD0-4A1A-9700-FC0D6CF168F0Q41546419-6085E0DE-89CE-43B8-A28E-1903B9F5D32CQ42443735-9F4B566C-378F-48A6-96D3-64DBE67279A3Q42450051-9457F867-D277-4006-8DD7-6BDA3C283ECCQ42460178-18B4A62C-528A-4D8E-84B3-91271D1E4012Q42471388-C17A4A56-E8DB-4F0B-8F27-612BAFEC4F39Q42477304-D7675D04-BE41-49AC-A039-5B8E23B1C9F3Q42481931-DBFFF986-3460-41D8-B590-B4925CB8D4E0Q42485208-C2BE14C0-7092-4D17-9D8A-75A86D64231EQ42488549-74E78498-CA55-46C5-8FBF-29E9E0686FA3Q42494151-3DE16665-CDFF-4D60-A8C4-8A3330080A17
P2860
European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
European guidelines for topica ...... disease, basal cell carcinoma.
@en
type
label
European guidelines for topica ...... disease, basal cell carcinoma.
@en
prefLabel
European guidelines for topica ...... disease, basal cell carcinoma.
@en
P2093
P356
P1476
European guidelines for topica ...... disease, basal cell carcinoma.
@en
P2093
A Sidoroff
C A Morton
L R Braathen
R-M Szeimies
P304
P356
10.1111/JDV.12031
P577
2012-11-26T00:00:00Z